Health economic analyses in reimbursement applications
Health economic analyses in applications for general reimbursement or general conditional reimbursement
Since 1998, it has been possible for companies that apply for general reimbursement or general conditional reimbursement for a medicine to enclose a health economic analysis to document that treatment with the medicine at the price indicated is cost-effective. It is voluntary to do so.
A health economic analysis is usually relevant in applications for general reimbursement for a medicine with documented health-related benefits compared to existing medicines and a higher treatment price, or if the medicine is used to treat a disease or a condition that is not treated with medicines today. If there is a risk that the medicine could be abused, it will often be less relevant or not relevant at all to make a health economic analysis.
Guideline on health economic analyses
We refer to our Guideline on health economic analyses of medicine (in Danish only), which describes how a health economic analysis should be made. The guideline has been written with assistance from:
- Professor, cand.oecon, PhD, Dorte Gyrd-Hansen
- Professor, cand.scient, MSc Health Econ, Jakob Kjellberg
- Professor, cand.oecon, Kjeld Møller Pedersen
- Professor, cand.oecon, PhD, Lars Holger Ehlers